Shares of Prestige Consumer Healthcare Inc (NYSE:PBH) have received a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $72.40.
A number of brokerages recently commented on PBH. ValuEngine downgraded Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a report on Friday, November 16th. Zacks Investment Research reissued a “hold” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, November 14th. DA Davidson increased their price target on Prestige Consumer Healthcare to $38.00 and gave the company a “neutral” rating in a report on Monday, November 5th. Finally, Jefferies Financial Group set a $38.00 price target on Prestige Consumer Healthcare and gave the company a “hold” rating in a report on Thursday, August 2nd.
In related news, EVP Timothy Connors sold 74,707 shares of the stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $38.96, for a total value of $2,910,584.72. Following the completion of the transaction, the executive vice president now owns 95,382 shares of the company’s stock, valued at $3,716,082.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.14% of the company’s stock.
Shares of PBH opened at $37.87 on Friday. The stock has a market capitalization of $1.96 billion, a P/E ratio of 14.68, a price-to-earnings-growth ratio of 1.88 and a beta of 1.04. Prestige Consumer Healthcare has a one year low of $27.84 and a one year high of $48.24. The company has a quick ratio of 1.38, a current ratio of 2.15 and a debt-to-equity ratio of 1.59.
Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 1st. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $239.36 million during the quarter, compared to the consensus estimate of $236.28 million. Prestige Consumer Healthcare had a return on equity of 11.82% and a net margin of 33.38%. Prestige Consumer Healthcare’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.61 earnings per share. On average, research analysts anticipate that Prestige Consumer Healthcare will post 2.88 EPS for the current year.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
See Also: Understanding Average Daily Trade Volume
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.